Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZRANB2 antisense RNA 2 (ZRANB2-AS2 or ZRANB2-DT) is a long non-coding antisense transcript generated at the ZRANB2 gene locus. Like other antisense RNAs, it is believed to regulate expression of its cognate gene, possibly through cis-acting transcriptional interference, RNA pairing, or modification of chromatin accessibility[4]. Antisense transcripts can modulate sense gene activity either in cis (local chromosomal effects) or in trans (RNA-mediated effects across loci), but direct functional evidence for ZRANB2-DT's biological or disease role is not currently available[4]. It does not encode a protein, nor is it known to serve as a receptor, transporter, or enzyme. There are no drugs or clinical biomarkers targeting ZRANB2-DT, and it is not considered a therapeutic target in current biomedical frameworks. The underlying ZRANB2 gene, conversely, encodes a zinc finger protein with key roles in RNA splicing, cancer biology, and cell cycle control[1][2][3], but ZRANB2-DT refers specifically to the *non-coding* antisense RNA product, not the protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZRANB2 antisense RNA 2 (ZRANB2-AS2).